Literature DB >> 33145854

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study.

Regina Stegherr1, Jan Beyersmann1, Valentine Jehl2, Kaspar Rufibach3, Friedhelm Leverkus4, Claudia Schmoor5, Tim Friede6.   

Abstract

The assessment of safety is an important aspect of the evaluation of new therapies in clinical trials, with analyses of adverse events being an essential part of this. Standard methods for the analysis of adverse events such as the incidence proportion, that is the number of patients with a specific adverse event out of all patients in the treatment groups, do not account for both varying follow-up times and competing risks. Alternative approaches such as the Aalen-Johansen estimator of the cumulative incidence function have been suggested. Theoretical arguments and numerical evaluations support the application of these more advanced methodology, but as yet there is to our knowledge only insufficient empirical evidence whether these methods would lead to different conclusions in safety evaluations. The Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) project strives to close this gap in evidence by conducting a meta-analytical study to assess the impact of the methodology on the conclusion of the safety assessment empirically. Here we present the rationale and statistical concept of the empirical study conducted as part of the SAVVY project. The statistical methods are presented in unified notation, and examples of their implementation in R and SAS are provided.
© 2020 The Authors. Biometrical Journal published by Wiley-VCH GmbH.

Entities:  

Keywords:  clinical trials; cumulative incidence function; drug safety; meta-regression; risk-benefit assessment

Year:  2020        PMID: 33145854     DOI: 10.1002/bimj.201900347

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  2 in total

1.  Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma.

Authors:  Katharina Seystahl; Felix Boakye Oppong; Emilie Le Rhun; Caroline Hertler; Roger Stupp; Burt Nabors; Olivier Chinot; Matthias Preusser; Thierry Gorlia; Michael Weller
Journal:  Neurooncol Adv       Date:  2022-07-07

Review 2.  Considerations of Competing Risks Analysis in Cardio-Oncology Studies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Yimei Li; Lova Sun; Danielle S Burstein; Kelly D Getz
Journal:  JACC CardioOncol       Date:  2022-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.